Abstract

Objectives:  We aim to present the retrospective results and statistical analysis of a year under COVID19 pandemic. Such analyses might be of great importance for management of individual cases of the disease on a day-to-day basis, as well as deciding upon certain restrictive measures as a whole; border-crossings movement, diagnostic testing and limiting travels in order to contain the pandemic of Covid 19. We hope our data contributes for further epidemiological investigations and future reference information.

Design and methods: We combined collected information from our rtPCR test results, statistical data within our hospital and epidemiological data according to our Regional Health Inspection. The collected data is cumulative and statistical analysis incredibly helpful and necessary. Our Molecular Diagnostics Unit is licensed within the territory of Bulgaria. Our methods were strict protocols from the guidelines of National Center for Infectious and Parasitic Diseases-Bulgaria; the kits we use are all CE, the overall concept in sync with the global regulations as from the CDC and the WHO. Statistical analyses were done with ANOVA tool.

Results: We give an overview of the collected data over the months of pandemic for the year 2020, as we observe several increases in the numbers of infected patients, but instead of having graphs with distinctive peaks we demonstrate a steady increase, giving a glimpse of the magnitude of the pandemic that followed after. The rtPCR test results are presented by pool data for both healthy travelling individuals and patients for confirming Covid diagnosis.

Discussion: The current report represents retrospective data and suggests the possibilities, available to nations and applicable locally and of immense importance near border-crossing regions in a situation of pandemic with such magnitude and without the immediate access to vaccines and reliable treatment resources for novel infectious outbreaks.

Keywords

  • Steatotic liver disease
  • Fatty liver
  • High Triglyceride
  • Type 2 diabetes mellitus
  • Hypertension